In a report released today, Ami Fadia from Needham maintained a Buy rating on Immuneering (IMRX – Research Report), with a price target of $12.00.
Ami Fadia has given his Buy rating due to a combination of factors that highlight Immuneering’s promising potential. The company is seen as well-positioned to enhance shareholder value, particularly as it continues to gather additional data from its ongoing Phase 2a trials for IMM-1-104. This includes data on median progression-free survival (mPFS) when combined with mGem/nab-Pac.
Furthermore, Immuneering is actively advancing its assets into other therapeutic areas, such as melanoma and non-small cell lung cancer (NSCLC), with ongoing enrollment in these indications. This strategic expansion and data generation are key reasons behind the positive outlook and Buy rating from Ami Fadia.
Fadia covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Bicycle Therapeutics, and Harmony Biosciences Holdings. According to TipRanks, Fadia has an average return of -3.5% and a 36.01% success rate on recommended stocks.